Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership [Yahoo! Finance]
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million